A5015768354- CAR-T cell therapy research
- Virus-based gene therapy research
- Immunotherapy and Immune Responses
- Phagocytosis and Immune Regulation
- Malaria Research and Control
- Immune Cell Function and Interaction
- Complement system in diseases
- Erythrocyte Function and Pathophysiology
- Viral Infections and Outbreaks Research
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- T-cell and B-cell Immunology
- CRISPR and Genetic Engineering
- Research on Leishmaniasis Studies
- Virology and Viral Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Animal Virus Infections Studies
- HIV Research and Treatment
- Acute Myeloid Leukemia Research
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Sarcoma Diagnosis and Treatment
Alberta Children's Hospital
2017-2024
University of Calgary
2018-2024
Institute of Cancer Research
2023-2024
Queen's University
2024
Alberta Children's Hospital Research Institute
2017-2022
University of Alberta
2017-2018
Second mitochondrial activator of caspase (Smac)-mimetic compounds and oncolytic viruses were developed to kill cancer cells directly. However, Smac-mimetic compound virus therapies also modulate host immune responses in ways we hypothesized would complement one another promoting anticancer T-cell immunity. We show that synergize driving CD8
Conventional dendritic cells (cDCs) generate protective cytotoxic T lymphocyte (CTL) responses against extracellular pathogens and tumors. This is achieved through a process known as cross-presentation (XP), and, despite its biological importance, the mechanism(s) driving XP remains unclear. Here, we show that cDC-specific pore-forming protein called apolipoprotein L 7C (APOL7C) up-regulated in response to innate immune stimuli recruited phagosomes. Association of APOL7C with phagosomes led...
Oncolytic viruses (OV) are designed to selectively infect and kill cancer cells, while simultaneously eliciting antitumour immunity. The mechanism is expected originate from infected cells. However, recent reports of tumour regression unaccompanied by cell infection suggest a more complex action. Here, we engineered vesicular stomatitis virus (VSV)ΔM51-sensitive VSVΔM51-resistant lines elucidate the role OV-infected non-cancer We found that, infections elicit oncolysis immunity as expected,...
CAR T therapy for solid tumors is limited by a lack of safe and uniformly expressed cell-surface targets. Here, we identify the MiT fusion-driven protein GPNMB as being highly, homogeneously, stably in primary relapsed translocation-positive alveolar soft part sarcoma (ASPS) renal cell carcinoma (tRCC). We developed GPNMB-targeting called GCAR1 that shows activity against patient-matched cells, organoids xenograft models. First-in-human treatment patient with metastatic ASPS was well...
In pregnancy, Plasmodium falciparum parasites express the surface antigen VAR2CSA, which mediates adherence of red blood cells to chondroitin sulfate A (CSA) in placenta. VAR2CSA antibodies are generally acquired during infection pregnancy and associated with protection from placental malaria. We observed previously that men children Colombia also had but origin these was unknown. Here, we tested whether vivax is an alternative mechanism acquisition antibodies. analyzed sera nonpregnant...
Abstract Type I conventional dendritic cells (cDC1s) are essential for the generation of protective cytotoxic T lymphocyte (CTL) responses against many types viruses and tumours. They do so by internalizing antigens from virally infected or tumour presenting them to CD8 + in a process known as cross-presentation (XP). Despite obvious biological importance XP, molecular mechanism(s) driving this remain unclear. Here, we show that cDC-specific pore-forming protein called apolipoprotein 7C...
The 15th International Oncolytic Virotherapy Conference took place in Banff, Alberta, and showcased diverse new approaches to enhancing oncolytic virus therapy. A reflective keynote highlighted industry challenges lessons. Presentations covered preclinical advancements, combination therapies, mechanisms biomarkers, many examples of clinical efficacy against various cancers.
Sarcomas are rare, difficult to treat, mesenchymal lineage tumours that affect children and adults. Immunologically-based therapies have improved outcomes for numerous adult cancers, however, these therapeutic strategies been minimally effective in sarcoma so far. Clinically relevant, immunologically-competent, transplantable pre-clinical models essential advance immunology research. Herein we show Cre-mediated activation of Kras G12D , deletion Trp53 the hindlimb muscles C57Bl/6 mice...
There is debate in the field of oncolytic virus (OV) therapy, whether a single viral dose, or multiple administrations, better for tumor control. Using intravital microscopy, we describe fate vesicular stomatitis (VSV) delivered systemically as first second dose. Following primary administration, VSV binds to endothelium, initiates infection and activates proinflammatory response. This initial OV dose induces neutrophil migration into limits replication. administered fails infect captured by...